>> Where does the spin-off get its money <<
Dunno. As you know, I don't favor splitting up the cash and the patents/licenses. I favor staying in biotech, finding another company that has an interest in adenosine receptors and/or GPCR. But, if SLV320 is what we're hoping for and if Goddard wasn't blowing bull, it shouldn't be hard to find a little cash to pay the attorneys. Or Newbie Company Inc. could retain an interest in return for paying the patent attorneys and maintenance fees.
I haven't gotten any response to my "idea" emails. That's what I like to see from a company, one-way communications. OTOH, she may be deleting them, thinking that they're spam.
Frustrating.
Yes, I mentioned Broach. Yes, he has the experience to recognize good ops. If we could get Carl's ear and he gave a damn about pocket change like this? He once had a passion for biotech, so it would work.
The buyer is still there. Unfortunately, so is a seller. BMY still?
I'm getting tired of looking for patent developments and following very old, cold leads ("SmithKline", etc.). They've let this sit until it's silly. Not selling, just disappointed that Icahn doesn't tend to all of his assets. |
